使用钠-葡萄糖协同转运蛋白2抑制剂的患者中的正常血糖性糖尿病酮症酸中毒
Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
作者信息
Isaacs Michelle, Tonks Katherine T, Greenfield Jerry R
机构信息
Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, New South Wales, Australia.
Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
出版信息
Intern Med J. 2017 Jun;47(6):701-704. doi: 10.1111/imj.13442.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis (euDKA) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）是一类越来越常用于治疗2型糖尿病的药物。已有报告称使用SGLT2i会引发血糖正常的糖尿病酮症酸中毒（euDKA）。临床医生需要了解如何识别和治疗这种并发症。我们描述了3例接受SGLT2i治疗的患者发生euDKA的病例。
Zotero 插件